BENGALURU, Feb 2 (Reuters) - Indian pharmaceutical firm
Jubilant Pharmova JUBA.NS on Friday reported a third-quarter
profit, compared to a loss a year earlier, on strong demand for
its radiopharma business.
The company posted a net profit of 668 million rupees ($8.06
million) for the quarter ended Dec. 31, compared to a loss of
156 million rupees a year ago.
The Noida-based firm's total revenue rose 8% to 16.77
billion rupees, with its radiopharma business - which involves
developing radioactive medications used to diagnose or treat
cancer - making up more than 40% of the total. The segment grew
22.7% during the quarter.
This is the fifth straight quarter that the company's
revenue has risen.
Jubilant Pharmova is involved in the manufacturing and
supply of radiopharmaceuticals with a network of 46
radio-pharmacies in the U.S.
The company's future revenue will be driven by its
high-margin radiopharmaceuticals division, according to
analysts.
Shares of Jubilant Pharmova rose as much as 7% after the
results, hitting a more than two-year high.
($1 = 82.8630 Indian rupees)
(Reporting by Ashish Chandra in Bengaluru; Editing by Sonia
Cheema)
((ashish.chandra@thomsonreuters.com; +91 7982114624;))